NPPA fixes the prices of 841 drugs under the Drugs (Prices Control) Order, 2013

Apr 03, 2018 | by Avantis RegTech Legal Research Team

A |  A

National Pharmaceutical Pricing Authority (NPPA) vide order dated April 02, 2018 has fixed the ceiling prices of 841 drugs under the Drugs (Prices Control) Order, 2013. These prices are revised as per the Annual Wholesale Price Index (WPI) @ 3.43812.

a)       The ceiling prices are applicable with effect from 01.4.2018 (ceiling prices are inclusive of Wholesale Price Index (WPI) @3.43812% for the year 2017 over 2016).

b)      In respect of any other scheduled formulation, for which ceiling price is not mentioned the manufacturer shall approach the NPPA for specific price approval for its formulations along with the relevant market data duly authenticated for fixation of the ceiling price.

c)       All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price.

d)      All the existing manufacturers of scheduled formulations having MRP lower than the ceiling price may revise the existing MRP of their formulations, on the basis of WPI @ 3.43812% for year 2017 in accordance with paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.

e)       The manufacturers may add goods and services taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

f)        The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

g)      Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

h)      Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

i)         The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.

j)         Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

[F. No. 8(56)/2017/D.P./NPPA-Div.-II]



Related Updates

Alternate Text

Get updates on the go on RuleZbook Mobile App.